Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging study of ND-L02-s0201 formulations in healthy volunteers
NCT03241264Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
01
Overview
Phase 1, randomised, open-label trial of ND-L02-s0201 in fibrosis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum plasma concentration up to 28 days, Time to maximum plasma concentration up to 28 days and 8 more. Started Aug 2016; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
fibrosis
Beyond the preview
Go deeper on NCT03241264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241264.